Kevin O'Leary: Psychedelic drugs 'far exceed' cannabis investment potential
- ByCNBC-
"Shark Tank" co-host Kevin O'Leary has multiple psychedelic drug company investments citing "incredible potential" compared to recreational cannabis.
Symbol | Exchange | Currency |
|---|
"Shark Tank" co-host Kevin O'Leary has multiple psychedelic drug company investments citing "incredible potential" compared to recreational cannabis.
Stigmatized drugs like psychedelic mushrooms and MDMA are key to a new era of mental illness treatment for conditions like depression and PTSD.
The following article is sponsored by Mind Cure. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Buy | Neutral | Sell | Sell |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Buy |
| Summary | Strong Buy | Strong Buy | Buy | Strong Sell | Neutral |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,278.38 | 2,284.72 | 2,250.00 | +49.34 | +2.21% | 1.60M | NASDAQ | |||
| 315.94 | 316.85 | 309.08 | +10.68 | +3.50% | 19.25M | NASDAQ | |||
| 12.98 | 14.34 | 12.57 | +0.21 | +1.64% | 207.59M | NYSE | |||
| 209.51 | 210.94 | 206.02 | +3.43 | +1.66% | 31.63M | NYSE | |||
| 172.29 | 172.98 | 170.85 | +1.44 | +0.84% | 1.23M | NYSE | |||
| 20.08 | 20.20 | 18.53 | +1.71 | +9.31% | 79.41M | NYSE | |||
| 36.56 | 37.50 | 35.27 | +1.36 | +3.86% | 1.05M | NASDAQ | |||
| 159.92 | 166.47 | 156.22 | -4.58 | -2.78% | 4.29M | NYSE | |||
| 15.21 | 15.43 | 14.97 | +0.28 | +1.88% | 418.49K | NYSE | |||
| 1.72 | 1.79 | 1.61 | +0.10 | +6.17% | 2.93M | NASDAQ | |||
| 88.23 | 88.70 | 87.25 | -1.79 | -1.99% | 3.25M | NYSE | |||
| 0.0007 | 0.00 | 0.00 | 0.00000 | 0.00% | 13.72M | OTC Markets | |||
| 51.14 | 51.59 | 47.80 | +2.46 | +5.05% | 1.63M | NASDAQ | |||
| 0.0002 | 0.00 | 0.00 | +0.0001 | +100.00% | 30.11M | OTC Markets | |||
| 0.001 | 0.00 | 0.00 | 0.000 | 0.00% | 285.70M | OTC Markets |
COMPASS Pathways PLC is a mental health care company. The Company is focused on developing treatments for people suffering with mental health challenges. It is initially focused on treatment-resistant depression (TRD). It is developing COMP360, a polymorphic crystalline formulation of psilocybin. Its COMP360 psilocybin therapy comprises administration of its COMP360 with psychological support from specially trained therapists with specific professional and educational qualifications. The psilocybin administration session lasts approximately six to eight hours, with patients supported by therapists in a non-directive manner. The psilocybin administration sessions are preceded by preparation sessions, in which patients are given a thorough orientation, and followed by integration sessions to help patients process the range of emotional and physical experiences facilitated by COMP360. The Company is developing COMP360 in conjunction with psychological support in a Phase-IIb trial.